CRISPR gene-editing controversy shows old ideas about East and West still prevail
By Calvin Wai-Loon Ho,
Econtimes
| 10. 24. 2016
The debate that followed initial experiments using the CRISPR-Cas9 genome editing tool show that old stereotypes about Asia still resonate in the West.
CRISPR-Cas9 is a gene editing tool that was first demonstrated US and Swedish labs in 2012. Basically, it uses segments of bacterial DNA that can make targeted cuts in a genome when paired with a specific guide protein (in this case, Cas9).
The technique is relatively uncomplicated compared with previous genome editing tools, which have been studied by scientists for more than 50 years. If applied to the genome of human germline cells, which pass on genetic material to produce human embryos, CRISPR-Cas9 has – at least in theory – the capability to alter humanity as we understand it.
Once certain genes are introduced or removed in germline cells (also known as gametes), the changes are passed onto the next generation. Given its potential to be misapplied towards eugenic ends and related ethical concerns, scientists generally agree that genetic modification of human gametes and embryos should not be done for reproductive purposes.
But it was less clear...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...